Pharmacokinetics and Pharmacodynamics Practice Questions

Q: What does a low Volume of Distribution (Vd) signify?

The drug does not accumulate significantly in tissues.. **Explanation:** **Volume of Distribution (Vd)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($Vd = \text{Total amount of drug} / \text{Plasma concentration}$) [1]. 1. **Why Option B is Correct:** A **low Vd** indicates that the drug is primarily confined to the vascular compartment (plasma) [1]. This occurs because the drug is either too large to leave the capillaries, or it is highly bound to plasma proteins (like albumin) [1]. Since the drug remains in the blood, it **does not accumulate significantly in peripheral tissues** or fat [1]. 2. **Why Other Options are Incorrect:** * **Option A:** Half-life ($t_{1/2}$) is related to both Vd and Clearance ($t_{1/2} = 0.693 \times Vd / CL$). While a low Vd *can* lead to a shorter half-life, it is not a rule; half-life depends equally on how fast the organs (liver/kidney) clear the drug. * **Option C:** Bioavailability refers to the fraction of the dose reaching systemic circulation [1]. It is independent of Vd, which describes what happens to the drug *after* it reaches the circulation. * **Option D:** This is the opposite of the truth. Drugs with low Vd usually exhibit **strong** (high) plasma protein binding, which keeps them trapped in the bloodstream [1]. **High-Yield Clinical Pearls for NEET-PG:** * **Low Vd ( 40L):** Drugs sequestered in tissues/fat (e.g., **Chloroquine, Digoxin, Amiodarone**) [1]. * **Hemodialysis:** Drugs with a **high Vd cannot be removed by hemodialysis** because they are not present in the blood in significant amounts. * **Loading Dose:** Vd is the primary determinant used to calculate the Loading Dose ($LD = Vd \times \text{Target Plasma Concentration}$) [1].

Q: Which of the following statements regarding drug transfer across the placenta is FALSE?

Drugs most commonly transfer through active transport.. ### Explanation **1. Why Option C is the Correct (False) Statement:** The primary mechanism for drug transfer across the placenta is **simple passive diffusion**, not active transport. Most drugs cross the placental barrier based on their concentration gradient. For a drug to cross effectively via diffusion, it typically needs to be **lipophilic, non-ionized, and have a low molecular weight (<500 Daltons)** [1]. While active transport does exist in the placenta (for nutrients like amino acids and vitamins), it is not the "most common" route for drugs. **2. Analysis of Incorrect Options (True Statements):** * **Option A:** In early pregnancy, the placental membrane is relatively thick, and surface area is small. As pregnancy progresses, the membrane thins and the surface area increases significantly, making drug transfer **greater in late pregnancy** compared to early pregnancy. * **Option B:** Most drugs cross the placenta. However, **Heparin** (large polar molecule) and **Insulin** (large polypeptide) are notable exceptions that do not cross the placental barrier in significant amounts, making them safe for use during pregnancy [1]. * **Option C:** **P-glycoprotein (P-gp)** is an efflux transporter located in the syncytiotrophoblast. It actively pumps certain xenobiotics back into the maternal circulation, acting as a protective mechanism for the fetus. **3. NEET-PG High-Yield Pearls:** * **Mnemonic for drugs that do NOT cross the placenta:** *"He Is Not Going"* (**H**eparin, **I**nsulin, **N**euromuscular blockers like d-Tubocurarine, **G**lycopyrrolate). * **Warfarin vs. Heparin:** Warfarin crosses the placenta (teratogenic); Heparin does not (safe). * **Fetal Ion Trapping:** Since fetal blood is slightly more acidic than maternal blood, basic drugs (like local anesthetics) can become ionized in the fetal circulation and get "trapped," leading to toxicity.

Q: A patient was given a 200 mg dose of a drug intravenously. If 100 mg was eliminated during the first 2 hours and the drug follows first-order elimination kinetics, how much of the drug will remain 6 hours after its administration?

25 mg. ### Explanation **1. Understanding the Correct Answer (D: 25 mg)** The core concept here is **First-Order Kinetics**, where a **constant fraction** of the drug is eliminated per unit of time. * **Initial Dose:** 200 mg. * **At 2 hours:** 100 mg was eliminated, meaning 100 mg remains. This indicates that 50% of the drug was cleared in 2 hours. Therefore, the **half-life ($t_{1/2}$)** of the drug is **2 hours**. * **At 4 hours (2nd half-life):** 50% of the remaining 100 mg is eliminated. Remaining = 50 mg. * **At 6 hours (3rd half-life):** 50% of the remaining 50 mg is eliminated. Remaining = **25 mg**. **2. Why Other Options are Incorrect** * **A (100 mg):** This is the amount remaining after only one half-life (2 hours). * **B (75 mg):** This value does not correspond to any standard half-life interval for this drug. * **C (50 mg):** This is the amount remaining after two half-lives (4 hours). If the drug followed *Zero-Order Kinetics* (constant amount eliminated), 50 mg would remain at 6 hours (50 mg lost every 2 hours), but the question specifies first-order. **3. NEET-PG Clinical Pearls & High-Yield Facts** * **First-Order Kinetics:** Most drugs follow this. Rate of elimination is directly proportional to plasma concentration. $t_{1/2}$ remains constant. * **Zero-Order Kinetics:** A constant *amount* is eliminated (e.g., **WATT**: **W**arfarin (at high doses), **A**lcohol, **T**heophylline, **T**olbutamide, **P**henytoin, **S**alicylates). $t_{1/2}$ is not constant. * **Steady State:** It takes approximately **4–5 half-lives** to reach steady-state concentration ($C_{ss}$) and the same amount of time to completely eliminate a drug from the body.

Q: Efficacy of a drug refers to:

The maximum response a drug can produce.. **Explanation:** **1. Why Option D is Correct:** **Efficacy (Intrinsic Activity)** is defined as the maximum effect ($E_{max}$) a drug can produce, regardless of the dose. It reflects the ability of a drug-receptor complex to initiate a biological response. In a graded dose-response curve, efficacy is represented by the **height (plateau)** of the curve. A drug with higher efficacy is more "effective" clinically than one with lower efficacy, even if the latter is more potent. **2. Why Other Options are Incorrect:** * **Option A:** This describes **Affinity**, which is the tendency of a drug to bind to a receptor. Affinity determines the drug's potency but not its maximum effect. * **Option B:** This describes the property of an **Agonist**. An agonist possesses both affinity (binding) and intrinsic activity (activation). * **Option C:** This describes **Potency**. Potency refers to the amount of drug (ED50) required to produce a response of a given intensity. On a dose-response curve, potency is indicated by the **left-right position** along the X-axis. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Efficacy vs. Potency:** Efficacy is clinically more important than potency. For example, Furosemide has higher efficacy than Thiazides; therefore, it is used in acute pulmonary edema where a massive response is needed. * **Full Agonist:** Has an intrinsic activity of 1. * **Antagonist:** Has affinity but **zero** intrinsic activity (efficacy = 0). * **Partial Agonist:** Has affinity but submaximal intrinsic activity (between 0 and 1). * **Inverse Agonist:** Has affinity but produces an effect opposite to that of an agonist (intrinsic activity = -1).

Q: Rate of absorption of an intramuscular injection is determined by which of the following factors?

Vascularity. **Explanation:** The rate of absorption of a drug from an intramuscular (IM) site is primarily determined by the **vascularity** (blood flow) of the muscle. 1. **Why Vascularity is Correct:** Absorption from an IM site occurs via simple diffusion from the muscle interstitial fluid into the capillaries. The rate-limiting step for small, water-soluble molecules is the **blood flow** to the area. Muscles with higher vascularity (e.g., Deltoid) exhibit faster absorption rates compared to those with lower vascularity (e.g., Gluteus maximus). This is also why exercise, which increases regional blood flow, accelerates IM drug absorption. 2. **Why Other Options are Incorrect:** * **Molecular Weight:** While it affects the *mechanism* of absorption (large molecules enter via lymphatics), the primary determinant of the *rate* in clinical IM administration is perfusion, not the size of the molecule. * **Volume of the Drug:** Volume primarily affects the pressure at the injection site and potential tissue damage/pain, but it does not dictate the physiological rate of systemic uptake. * **Bore of the Needle:** This determines the ease of administration (viscosity management) and patient discomfort, but has no physiological impact on how the drug crosses the capillary membrane once deposited. **High-Yield Clinical Pearls for NEET-PG:** * **Order of Absorption Rate:** Deltoid > Vastus lateralis > Gluteus maximus (due to decreasing vascularity). * **Depot Preparations:** Drugs like Penicillin G Benzathine or Haloperidol Decanoate are designed as insoluble salts in oil to *intentionally* slow down absorption despite high vascularity. * **Shock/Hypotension:** In patients with circulatory collapse, IM absorption is significantly impaired due to peripheral vasoconstriction; hence, the **Intravenous (IV)** route is preferred in emergencies.

Q: All of the following are Phase II reactions except?

Cyclization. **Explanation:** Drug metabolism (biotransformation) typically occurs in two phases. **Phase I (Nonsynthetic) reactions** involve the introduction or unmasking of a functional group (–OH, –NH2, –SH), while **Phase II (Synthetic) reactions** involve the attachment of an endogenous moiety to the drug to make it more water-soluble for excretion. **Why Cyclization is the correct answer:** Cyclization is a **Phase I reaction**. It involves the formation of a ring structure from an open-chain compound (e.g., proguanil to cycloguanil). Other Phase I reactions include Oxidation (most common), Reduction, Hydrolysis, and Decarboxylation. **Analysis of Incorrect Options (Phase II Reactions):** Phase II reactions involve **conjugation**. * **A. Acetylation:** A Phase II reaction mediated by N-acetyltransferase (e.g., Isoniazid, Hydralazine). * **B. Methylation:** A Phase II reaction (e.g., Adrenaline to Metanephrine). * **C. Glycine conjugation:** A Phase II reaction (e.g., Salicylates conjugated with glycine to form hippuric acid). * *Other Phase II reactions include Glucuronidation (most common), Sulfation, and Glutathione conjugation.* **High-Yield NEET-PG Pearls:** 1. **Glucuronidation** is the most common Phase II reaction and the only one that occurs in the microsomal fraction (smooth ER); others are non-microsomal. 2. **Oxidation** is the most common Phase I reaction, primarily mediated by **Cytochrome P450** enzymes. 3. **Phase II before Phase I:** While the sequence is usually I then II, some drugs like **Isoniazid** undergo Phase II (Acetylation) followed by Phase I (Hydrolysis). 4. **Slow Acetylators:** Genetic polymorphism in acetylation (NAT2 enzyme) can lead to toxicity with drugs like Isoniazid (peripheral neuropathy) and Hydralazine (Lupus-like syndrome).

Q: An antagonist that generates an action opposite to a substance by binding to different receptors is known as:

Physiological antagonist. ### Explanation **1. Why Physiological Antagonist is Correct:** A **physiological (or functional) antagonist** occurs when two drugs act on **different receptors** and produce **oppositely directed** physiological effects on the same system. Unlike pharmacological antagonism, there is no competition for the same receptor site. Instead, the drugs activate independent pathways that cancel each other out functionally. * *Classic Example:* **Histamine** (acts on H1 receptors to cause bronchoconstriction) vs. **Adrenaline** (acts on β2 receptors to cause bronchodilation). **2. Why Other Options are Incorrect:** * **Physical Antagonist (A):** Based on the physical property of the drug. For example, **Charcoal** adsorbs alkaloids, preventing their absorption. * **Chemical Antagonist (B):** Two substances react chemically to form an inactive product. No receptors are involved. For example, **Chelating agents** (EDTA) binding to heavy metals or **Antacids** neutralizing gastric acid. * **Pharmacologic Antagonist (D):** The antagonist binds to the **same receptor** as the agonist, preventing the agonist from binding. This can be competitive (reversible) or non-competitive (irreversible). **3. NEET-PG Clinical Pearls & High-Yield Facts:** * **Adrenaline in Anaphylaxis:** Adrenaline is the "physiological antagonist" of histamine and is the drug of choice for anaphylactic shock because it rapidly reverses life-threatening airway obstruction and hypotension via different receptors. * **Glucagon and Insulin:** These are physiological antagonists regarding blood glucose levels (Glucagon increases glucose via glucagon receptors; Insulin decreases it via insulin receptors). * **Key Distinction:** If the question mentions "same receptor," think **Pharmacologic**; if it mentions "different receptor/same system," think **Physiological**.

Question 1

What does a low Volume of Distribution (Vd) signify?

Accepted Answer

The drug does not accumulate significantly in tissues.

Answer

The drug has a short half-life.

Answer

The drug has low bioavailability.

Answer

The drug exhibits weak plasma protein binding.

Question 2

Which of the following statements regarding drug transfer across the placenta is FALSE?

Accepted Answer

Drugs most commonly transfer through active transport.

Answer

Transfer across the placenta is lesser in early pregnancy.

Answer

Most drugs can cross the placenta to some extent, except heparin and insulin.

Answer

P-glycoprotein is present in the placenta.

Question 3

Therapeutic index of a drug is a measure of its?

Accepted Answer

Safety

Answer

Efficacy

Answer

Potency

Answer

Selectivity

Question 4

A patient was given a 200 mg dose of a drug intravenously. If 100 mg was eliminated during the first 2 hours and the drug follows first-order elimination kinetics, how much of the drug will remain 6 hours after its administration?

Accepted Answer

25 mg

Answer

100 mg

Answer

75 mg

Answer

50 mg

Question 5

Which of the following is a characteristic of a highly ionized drug?

Accepted Answer

Is excreted mainly by the kidney

Answer

Accumulates in cellular lipids

Answer

Crosses the placental barrier easily

Answer

Is well absorbed from the intestine

Question 6

Efficacy of a drug refers to:

Accepted Answer

The maximum response a drug can produce.

Answer

The affinity of the drug to bind to the receptor.

Answer

The affinity of the drug that binds to the receptor and activates it.

Answer

The dose required to produce a response.

Question 7

An intravenous bolus dose of thiopentone leads to loss of consciousness within 10-15 seconds. The patient regains consciousness in just a few minutes. This is because it is:

Accepted Answer

Redistributed from brain to other body tissues

Answer

Renally excreted

Answer

Exhaled rapidly

Answer

Rapidly metabolized by hepatic enzymes

Question 8

Rate of absorption of an intramuscular injection is determined by which of the following factors?

Accepted Answer

Vascularity

Answer

Molecular weight of the drug

Answer

Volume of the drug

Answer

Bore of the needle

Question 9

All of the following are Phase II reactions except?

Accepted Answer

Cyclization

Answer

Acetylation

Answer

Methylation

Answer

Glycine conjugation

Question 10

An antagonist that generates an action opposite to a substance by binding to different receptors is known as:

Accepted Answer

Physiological antagonist

Answer

Physical antagonist

Answer

Chemical antagonist

Answer

Pharmacologic antagonist

Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics — MCQs

On this page

Practice by Chapter

Want unlimited practice?